Cognitive and Neural Effects of ARA290 (CONEARA)

Summary: Researchers are exploring whether ARA290, a peptide without EPO’s blood-related side effects, can replicate EPO’s potential antidepressant effects on brain function. The study aims to determine if a single dose of ARA290 can positively influence emotional processing in healthy individuals compared to a placebo after one week.

Link: Leiden University Medical Center

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

Summary: This study aims to see if ARA 290 can help treat nerve pain in people with sarcoidosis by promoting anti-inflammatory and healing effects in the body. Participants will receive either ARA 290 or a placebo for 28 days and be evaluated over 16 weeks for safety and changes in their symptoms and nerve health.

Link: Araim Pharmaceuticals, Inc.

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

Summary: The study aims to assess if ARA 290, a non-blood-related erythropoietin analogue, can improve blood glucose levels and insulin secretion in people with prediabetes or untreated type 2 diabetes. It will also examine the drug’s impact on insulin sensitivity, inflammation markers, and overall safety regarding blood, kidney, liver, and lipid health.

Link: Claes-Göran Östenson, Karolinska Institutet

Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study

Summary: The study investigated the safety and effectiveness of ARA 290 in reducing symptoms of small fiber neuropathy (SFN) in 22 sarcoidosis patients over four weeks. Results showed that ARA 290 significantly improved neuropathy symptoms and some quality of life measures without causing any safety concerns.

Link: Department of Anesthesiology, Leiden University Medical Center

ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes

Summary: The study found that ARA 290, a peptide inspired by erythropoietin, improved blood sugar levels, lipid profiles, and reduced neuropathic pain in individuals with type 2 diabetes over a 56-day period without identifying any safety concerns. Additionally, ARA 290 showed potential in regenerating nerve fibers, suggesting it could be beneficial for metabolic control and neuropathy in these patients, warranting further clinical investigation.

Link: Araim Pharmaceuticals

Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice

Summary: This study found that a peptide called ARA290 can reduce depression-like behavior in stressed mice, similar to the antidepressant fluoxetine, by exerting anti-inflammatory effects. ARA290 did this without significantly affecting blood components, and also reduced stress-induced changes in immune cells and brain inflammation.

Link: Beijing Institute of Basic Medical Sciences

The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain

Summary: Sarcoidosis can cause debilitating neuropathic pain, and current treatments often have limited effectiveness or significant side effects. A new drug, ARA 290, shows promise in relieving pain for these patients without major safety concerns, with further studies planned to confirm its benefits.

Link: Leiden University Medical Center, Department of Anesthesiology

ARA 290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-Term Relief of Neuropathic Pain Coupled with Suppression of the Spinal Microglia Response

Summary: This study explored the effects of the peptide ARA290 on neuropathic pain in rats and found that it effectively reduced pain symptoms in a dose-dependent manner by decreasing the activity of specific inflammatory cells in the spinal cord. The results suggest that ARA290 could potentially alleviate neuropathic pain by targeting these immune cells to suppress central inflammation.

Link: Department of Anesthesiology, Leiden University Medical Center

ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury

Summary: This study found that administering ARA290, a non-erythropoietic derivative of erythropoietin, improved kidney function and reduced tissue damage in pigs after induced kidney injury. The results suggest ARA290 might be a safer alternative to high-dose erythropoietin for protecting kidneys during similar injuries, warranting further investigation for potential clinical use.

Link: Department of Surgery, University of Groningen

Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action

Summary: The study investigated the potential antidepressant effects of ARA290, an EPO-analog peptide, by analyzing its impact on emotional processing in healthy participants. Results showed that while ARA290 influenced certain aspects of emotional and facial recognition processing, it did not conclusively demonstrate an antidepressant-like profile, prompting further research on different dosages and timing.

Link: Institute of Psychology, Leiden University